Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma

Clinical Epigenetics

Volumn 2, Issue 2, 2011, Pages 417-418

  Bavi, Prashant ^a   Abubaker, Jehad ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Uddin, Shahab ^a   Siraj, Abdul K ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REGULATOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

A20 GENE; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GENE DELETION; GENE DOSAGE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; NONSENSE MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84856275012     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1007/s13148-011-0049-z     Document Type: Article

References (11)

1. Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J et al (2009) A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 24:483-7
2. Coornaert B, Carpentier I, Beyaert R (2009) A20: central gatekeeper in inflammation and immunity. J Biol Chem 284:8217-8221
3. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y et al (2009) TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114:2467-2475
4. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F (2009) Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 115:4946-4958
5. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature 459:712-716
6. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M et al (2004) Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24:675-681 (Pubitemid 38625006)
7. Rakitina TV, Vasilevskaya IA, O'Dwyer PJ (2003) Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res 63:8600-8605 (Pubitemid 38064033)
8. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A et al (2007) Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25:3930-3935 (Pubitemid 47477270)
9. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G et al (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206:981-989
10. Stilo R, Varricchio E, Liguoro D, Leonardi A, Vito P (2008) A20 is a negative regulator of BCL10-and CARMA3-mediated activation of NF-kappaB. J Cell Sci 121:1165-1171 (Pubitemid 351753500)
11. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694-699 (Pubitemid 39061687)